Theralink’s Quarterly Newsletter

Theralink → Theralink’s Quarterly Newsletter

Coming Soon

Search for:

Theralink® Technologies Expands Adoption of its Precision Medicine Technology in the Biopharmaceutical Industry
Avera Health and Theralink® Technologies Announce Strategic Collaboration to Accelerate Adoption of Precision Oncology and Personalized Cancer Care
Theralink® Technologies Announces New PLA Code and Information Submittal to Medicare Contractors for the Theralink Assay for Advanced Breast Cancer Patients
Early Results Show >90% Actionability and >75% Clinical Utility for Theralink® Technologies’ Lab Developed Test for Advanced Breast Cancer Patients
Theralink® Technologies Announces Change of Ticker Symbol and CUSIP

Theralink Technologies intends to be a market leader in precision medicine for more effective cancer treatments

Theralink® Technologies Expands Adoption of its Precision Medicine Technology in the Biopharmaceutical Industry
Avera Health and Theralink® Technologies Announce Strategic Collaboration to Accelerate Adoption of Precision Oncology and Personalized Cancer Care
Theralink® Technologies Announces New PLA Code and Information Submittal to Medicare Contractors for the Theralink Assay for Advanced Breast Cancer Patients